Cargando…
Non-Dopaminergic Therapies
Currently all aspects of Parkinson’s disease (PD) treatment are less than ideal and would benefit from new interventions. We focus on problems associated with brain neurotransmitters amenable to more specific subreceptor and temporal manipulation. In addition, we consider potentially treatable CNS n...
Autores principales: | Nutt, John G., Bohnen, Nicolaas I. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311374/ https://www.ncbi.nlm.nih.gov/pubmed/30584157 http://dx.doi.org/10.3233/JPD-181472 |
Ejemplares similares
-
Dopaminergic Vulnerability and Motor Impairments in Older Adults: Need for Targeted Pharmacotherapy
por: Bohnen, Nicolaas
Publicado: (2020) -
Dopaminergic Signaling: Driver of Mobility Resilience and Moderator of Response to Pharmacotherapy
por: Rosano, Caterina, et al.
Publicado: (2020) -
GAIT SLOWING AMONG FRAIL OLDER ADULTS: IS HIGHER DOPAMINERGIC SIGNALING PROTECTIVE?
por: Rosano, Caterina, et al.
Publicado: (2019) -
Emerging non-invasive therapeutic approaches targeting hypocholinergic neural systems in Parkinson’s disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2022) -
Sleep Disturbance as Potential Risk and Progression Factor for Parkinson’s Disease
por: Bohnen, Nicolaas I., et al.
Publicado: (2019)